Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-MSH6 Antibody (R3M88)

Catalog #:   RHE93108 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2b
Applications: ELISA, FCM, IF, IHC, WB
Accession: P52701
Overview

Catalog No.

RHE93108

Species reactivity

Human

Host species

Mouse

Isotype

IgG2b

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000, WB: 1:500-1:2000

Target

DNA mismatch repair protein Msh6, MutS protein homolog 6, MSH6, GTBP, hMSH6, GTMBP, G/T mismatch-binding protein, MutS-alpha 160 kDa subunit, p160

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P52701

Applications

ELISA, FCM, IF, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3M88

Data Image
  • Flow Cytometry
    Flow cytometric analysis of Hela cells using MSH6 mouse mAb (green) and negative control (red).
  • Immunofluorescence
    Immunofluorescence analysis of Hela cells using MSH6 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human colon tissues using MSH6 mouse mAb with DAB staining.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human brain tumor tissues using MSH6 mouse mAb with DAB staining.
  • Western blot
    Western blot analysis using MSH6 mouse mAb against SH-SY5Y (1), Hela (2), PC-3 (3), HCT116 (4), HEK293 (5), A549 (6), and HepG2 (7) cell lysate.
  • Western blot
    Western blot analysis using MSH6 mouse mAb against SH-SY5Y (1), Hela (2), PC-3 (3), HCT116 (4), HEK293 (5), A549 (6), and HepG2 (7) cell lysate.
References

[Microsatellite instability as a possible diagnostic marker of the gastric mucosa dysplasia]., PMID:40531552

Immunohistochemical and molecular evolutionary features of jejunoileal adenocarcinoma unveiled through comparative analysis with colorectal adenocarcinoma., PMID:40403397

Detecting microsatellite instability in cancer via multiplexed orthogonal gap-enhanced Raman tags., PMID:40386153

Microsatellite Status, Tumor Budding, CD3 and CD8 T Cell Densities in Relation to Invasiveness, Lymph Node Involvement in Colorectal Adenocarcinoma., PMID:40263681

Comparison of survival outcomes for patients with Lynch vs non-Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy., PMID:39932790

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review., PMID:39931054

[Application of PMS2 and MSH6 double-antibody detection in screening of mismatch repair deficient tumors]., PMID:39863527

Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome., PMID:39660603

Simplifying Mismatch Repair Deficiency Screening in Endometrial Adenocarcinoma: Immunohistochemistry with Two-Antibody Panel (PMS2 and MSH6)., PMID:39471035

Intraoperative rapid immunohistochemistry of microsatellite instability using non-contact alternating current electric field mixing., PMID:39443409

Gaucher-like crystal-storing histiocytosis associated with kappa chain myeloma: A case report with next generation sequencing study., PMID:39357187

Single Center Characterization of a Cohort of Salivary Gland Carcinomas., PMID:39337873

Universal testing in endometrial cancer in Sweden., PMID:39175077

Intriguing Insights From 100 Consecutive Colorectal Cancer Cases in Mid-Kerala: Sparse BRAF Gene Mutations and Mismatch Repair Deficiency (MMR-D)., PMID:39119381

Comparison of antigenicity between frozen section vs non-frozen section tissue blocks: An immunohistochemical study of antibodies commonly used in gynecologic pathology., PMID:39110415

Analysis of translesion polymerases in colorectal cancer cells following cetuximab treatment: A network perspective., PMID:39102671

Mismatch repair deficiency: how reliable is the two-antibody approach? A national real-life study., PMID:38859771

Diagnostic and prognostic assessments of adrenocortical carcinomas by pathological features, immunohistochemical markers and reticular histochemistry staining., PMID:38802933

Assessing Mismatch Repair Expression by Immunohistochemistry in Colorectal Adenocarcinoma -Insight from a Tertiary Care Centre., PMID:38774931

The Relationship of Microsatellite Instability with BRAF and p53 Mutations and Histopathological Parameters in Colorectal Adenocarcinoma., PMID:38684491

[Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status]., PMID:38591901

HER2-low and Overexpression in Mucinous Ovarian Cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring., PMID:38436360

Clinicopathological features and evaluation of microsatellite stability of colorectal carcinoma with cribriform comedo pattern., PMID:38394410

Next-generation sequencing and immunohistochemistry approaches for microsatellite instability detection in endometrial cancer., PMID:38279425

The relationship between DNA mismatch repair gene and other prognostic parameters in pancreatic adenocarcinoma., PMID:38173349

Clinicopathologic features of conjunctival MALT lymphomas refractory to radiation therapy., PMID:38101452

Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas., PMID:38029026

Deficient Mismatch Repair Proteins in Gastric Mixed Neuroendocrine Non-Neuroendocrine Neoplasm: A Rare Case Report., PMID:37900850

Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)., PMID:37819940

Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer., PMID:37741509

Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters., PMID:37664303

Mismatch Repair Protein Expression in Endometrial Cancer: Assessing Concordance and Unveiling Pitfalls in Two Different Immunohistochemistry Assays., PMID:37623510

Early-Onset/Young-Onset Colorectal Carcinoma: A Comparative Analysis of Morphological Features and Biomarker Profile., PMID:37621838

Using Proteome Microarray and Gene Expression Omnibus Database to Screen Tumour-Associated Antigens to Construct the Optimal Diagnostic Model of Oesophageal Squamous Cell Carcinoma., PMID:37433700

A Japanese case of ovarian mucinous adenocarcinoma with germline double variants of MSH2 and BRCA2., PMID:37420004

Mixed acinar-neuroendocrine carcinoma of the pancreas with positive for microsatellite instability: a case report and review of the literature., PMID:37386324

MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration., PMID:37354330

The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes., PMID:37060883

Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors., PMID:37055532

Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature., PMID:36974818

B cell class switch recombination is regulated by DYRK1A through MSH6 phosphorylation., PMID:36927854

Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report., PMID:36582237

[Microsatellite instability in gastric cancer is a predictor of a favorable prognosis]., PMID:36469712

Mismatch repair proteins expression and tumor-infiltrating T-cells in colorectal cancer., PMID:36276483

Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis., PMID:36104536

An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma., PMID:36051725

Mismatch Repair Deficiency in Adult Granulosa Cell Tumors: an Immunohistochemistry-based Preliminary Study., PMID:35960021

A Human MSH6 Germline Variant Associated With Systemic Lupus Erythematosus Induces Lupus-like Disease in Mice., PMID:35708944

Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability., PMID:35592855

A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months., PMID:35487690

Datasheet

Document Download

Anti-MSH6 Antibody (R3M88).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-MSH6 Antibody (R3M88) [RHE93108]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only